🔗 Share this article

While the United States continues making historic changes to its vaccine schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about Covid vaccinations during the pandemic and has concentrated on potential deaths after COVID-19 immunization in her short time at the FDA.

Planned Changes to Childhood Vaccine Schedule

Agency leaders planned to announce major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with many the international standard with insufficient data for improved outcomes. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s CDER, the fifth appointee to run the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric shot schedules in the US in order to be more in line with Denmark, a society with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Qualifications

Høeg has no apparent background in medication creation, oversight or leadership, which has been typical for previous heads of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past heads of the center would “grasp laws and regulations and the science of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who led the center have had.”

The drug center has an vast range of responsibilities at the agency, Woodcock stated.

“Many people just zeroes in on the novel medication approvals, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be managed,” she explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which supervises over 5,000 employees. “It is a huge management job, if you perform it correctly,” she said.

Official Statement and Controversial Initiatives

When asked about concerns about Høeg’s credentials and whether this selection indicates greater collaboration among agency officials on vaccines, a press secretary said that the “concerns rely on incorrect presumptions”.

“Her resume is consistent with the functions of her job,” the spokesperson stated, noting the time Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a controversial one-day drug-approval program that reportedly concerned her predecessors. “By what process are these therapies being picked for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, except for vaccines.”

Public History on Vaccines

Regarding vaccines, Høeg has a more documented, if concerning, history, some experts observe. She released a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the new administration featured altering rules for new vaccines and ending “optional” immunizations, she remarked following the vote on a online show. At the agency, Høeg has according to sources floated the idea of preventing teenage boys from getting COVID-19 vaccinations.

“She is an complete ideologue who starts off with her beliefs and works backwards to retrofit the data in a highly misleading, untruthful way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|